US pharmaceutical and biotech company Moderna, known for its COVID-19 vaccines, is expected to begin human trials for two HIV vaccines this week.
The trials are expected to begin as early as August 19 and last until May 2023, according to the US National Institute of Health’s clinical trial registry.
The vaccines will use mRNA technology in this revolutionary advancement to see if the mRNA technology will be effective in combating the virus.
Phase one of Moderna’s trails will include fifty-six adult participants aged between 18 to 50 years of age. The aim of the first phase is to assess the safety of the vaccine and to chart how successful it is in attacking the HIV virus and producing antibodies.